Novo Nordisk's GLP-1 receptor agonist semaglutide has shown efficacy as a treatment for metabolic dysfunction-associated steatohepatitis (MASH) in a phase 3 trial, potentially teeing up US and ...

Last week's survey by the British Potato Council revealed that we prefer mash to chips. So is this good news for our health? Nutritionally speaking, both mash and chips are good sources of energy ...

But as with all T-shirts — black, white, or otherwise — the Perfect One often proves elusive. And even though the idea of the “perfect” long-sleeved tee is subjective, that didn’t stop ...